Journal: Infectious disease clinics of North America

Article Title: Trichomoniasis

doi: 10.1016/j.idc.2023.02.001

Figure Lengend Snippet: 2A: 96-well plate used for 5-nitroimidazole drug susceptibility testing. 2B: Graphical representation of a portion of the 96 well plate for the 5-nitroimidazole drug susceptibility testing. Rows A and H are DMSO control lanes, while lanes B-G contain the 5-nitroimdazoles tested for specific T. vaginalis isolates tested in triplicates. 50 μl of media is initially added to each well. Next, 50 μl of drug/media is added to column 1 rows B-G, while 50 μl of DMSO/media are added to A and H and then serially diluted from left to right (column 1 [400 μg/ml] to column 12 [0.2 μg/ml]). 150 μl of the T. vaginalis sample is added to each well from the lowest concentration to the highest (column 12 [0.2 μg/ml] to column 1 [400 μg/ml]). The plates are then incubated for 48 to 52 hours before being read on an inverted microscope. MLC is determined when no motile TV is observed for all three wells with the same concentration.

Article Snippet: The InPouch ® T. vaginalis culture system (BioMed Diagnostics, White City, OR) is the most commonly used culture method and has a sensitivity of 44-81% and specificity of 100%.

Techniques: Concentration Assay, Incubation, Inverted Microscopy

Journal: Infectious disease clinics of North America

Article Title: Trichomoniasis

doi: 10.1016/j.idc.2023.02.001

Figure Lengend Snippet: Diagnostic tests for Trichomonas vaginalis

Article Snippet: The InPouch ® T. vaginalis culture system (BioMed Diagnostics, White City, OR) is the most commonly used culture method and has a sensitivity of 44-81% and specificity of 100%.

Techniques: Diagnostic Assay, Microscopy, Incubation, Solana Trichomonas Assay, AmpliVue Trichomonas assay

Journal:

Article Title: Impact of Trichomonas vaginalis Transcription-Mediated Amplification-Based Analyte-Specific-Reagent Testing in a Metropolitan Setting of High Sexually Transmitted Disease Prevalence ▿

doi: 10.1128/JCM.00564-08

Figure Lengend Snippet: Rates of sexually transmitted agent detection for 1,086 primary genital specimens included in a retrospective evaluation of a Trichomonas vaginalis molecular ASR

Article Snippet: Aliquots (400 μl) were subsequently subjected to Gen-Probe T. vaginalis molecular analyte-specific-reagent (ASR) testing.

Techniques:

Journal:

Article Title: Impact of Trichomonas vaginalis Transcription-Mediated Amplification-Based Analyte-Specific-Reagent Testing in a Metropolitan Setting of High Sexually Transmitted Disease Prevalence ▿

doi: 10.1128/JCM.00564-08

Figure Lengend Snippet: Percentage of positive Trichomonas vaginalis results determined by direct saline preparation (open bars) and molecular ASR (solid bars) and stratified by health care entity for 1,086 female genital specimens. Asterisks denote P values of <0.0002.

Article Snippet: Aliquots (400 μl) were subsequently subjected to Gen-Probe T. vaginalis molecular analyte-specific-reagent (ASR) testing.

Techniques:

Journal:

Article Title: Impact of Trichomonas vaginalis Transcription-Mediated Amplification-Based Analyte-Specific-Reagent Testing in a Metropolitan Setting of High Sexually Transmitted Disease Prevalence ▿

doi: 10.1128/JCM.00564-08

Figure Lengend Snippet: Direct comparisons of Trichomonas vaginalis direct saline preparation and molecular ASR results, delineated by health care entity, in a retrospective evaluation of 1,086 primary genital specimens.

Article Snippet: Aliquots (400 μl) were subsequently subjected to Gen-Probe T. vaginalis molecular analyte-specific-reagent (ASR) testing.

Techniques:

Journal:

Article Title: Impact of Trichomonas vaginalis Transcription-Mediated Amplification-Based Analyte-Specific-Reagent Testing in a Metropolitan Setting of High Sexually Transmitted Disease Prevalence ▿

doi: 10.1128/JCM.00564-08

Figure Lengend Snippet: Odds ratios for concomitant molecular detection of Chlamydia trachomatis - or Neisseria gonorrhoeae -specific nucleic acid on the basis of Trichomonas vaginalis detection by direct saline preparation or molecular ASR

Article Snippet: Aliquots (400 μl) were subsequently subjected to Gen-Probe T. vaginalis molecular analyte-specific-reagent (ASR) testing.

Techniques:

Journal:

Article Title: Impact of Trichomonas vaginalis Transcription-Mediated Amplification-Based Analyte-Specific-Reagent Testing in a Metropolitan Setting of High Sexually Transmitted Disease Prevalence ▿

doi: 10.1128/JCM.00564-08

Figure Lengend Snippet: Rates of Trichomonas vaginalis detection by direct saline preparation and subsequent molecular ASR from 508 primary genital specimens collected in an outpatient physician group setting, delineated by laboratory-based and point-of-care-based microscopy

Article Snippet: Aliquots (400 μl) were subsequently subjected to Gen-Probe T. vaginalis molecular analyte-specific-reagent (ASR) testing.

Techniques:

Journal: Journal of acquired immune deficiency syndromes (1999)

Article Title: Characterization of HIV seroconverters in a TDF/FTC PrEP study: HPTN 067/ADAPT

doi: 10.1097/QAI.0000000000001374

Figure Lengend Snippet: Laboratory test results are shown for 6 participants who were not randomized (Figure 1A, Cases 1–6) and 6 participants who were randomized to the daily, time-driven, or event-driven study arms (Figure 1B–D, Cases 7–12). The shaded area indicates the period when participants received once-weekly directly observed therapy (DOT); four participants did not receive DOT at the week 4 visit because one or both of the HIV rapid tests was positive (Cases 1, 2, 3, and 5). One participant was not randomized due to pregnancy (Case 6); this participant was followed during the study, but did not receive PrEP in the SAT (self-administered therapy) phase. The remaining six participants were randomized to one of three PrEP regimens at week 6 (SAT). PrEP was discontinued when one or both of the HIV rapid tests was reactive; in one case, the participant stopped PrEP at the end of the SAT phase (week 30) and had reactive rapid tests at the next visit in the follow-up phase (at week 34, Case 11). Reactive/positive test results are shown in bold font. Two HIV rapid tests were performed in parallel at study sites (Site rapid); results are shown as reactive (R) or non-reactive (NR). HIV infection was confirmed at study sites using the APTIMA HIV-1 RNA Qualitative Assay (Site RNA Qual; limit of detection: <40 copies/mL, Hologic, Marlborough, Massachusetts). Additional testing was performed retrospectively at the HPTN Laboratory Center (LC). This included two 4th generation tests (LC Arc: ARCHITECT HIV Ag/Ab Combo Assay, Abbott Diagnostics, Weisbaden, Germany; LC BR: GS HIV Combo Ag/Ab Enzyme Immunoassay, Bio-Rad Laboratories, Redmond, WA). The signal to cut-off ratios (S/C) for the 4th generation tests are shown in parenthesis; a ratio <1 is considered to be nonreactive. HIV infection was confirmed using a Western blot assay (LC WB, Genetics System HIV-1 Western blot test, Bio-Rad Laboratories) and a discriminatory assay (LC Disc, the Multispot HIV-1/HIV-1 Rapid test or Geenius HIV 1/2 Supplemental Assay, Bio-Rad Laboratories]); an asterisk indicates that the Geenius assay was used; other samples were tested using the Multispot assay. Western blot results were reported as positive (P), indeterminate (IND), or negative (N). Viral load testing (LC VL) was performed using a modified version of the COBAS AMPLICOR HIV-1 MONITOR test (Roche Diagnostics, Branchburg, NJ) with a lower limit of detection of 400 HIV RNA copies/mL. HIV drug resistance testing was performed using the ViroSeq HIV-1 Genotyping System (Resist VS) and a next generation sequencing assay with a mutation cut-off of 2% (Resist NGS). Mutations associated with resistance to tenofovir (TFV) and emtricitabine (FTC) are shown in bold font; other major drug resistance mutations are shown in regular font. TFV and FTC testing was performed using plasma samples (Plasma TFV/FTC, reported as ng/mL). TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTV-TP) testing was performed using peripheral blood mononuclear cell PBMC samples (PBMC TFV-DP, reported as fmol/106 cells; PBMC FTC-TP, reported as pmol/106 cells), with one exception: testing for TFV-DP and FTC-TP was performed using DBS samples in Case 8 (reported as fmol/punch). Antiretroviral (ARV) test results below the limit of detection for each assay are shown with a dash (−). The s/c values for the 4th generation tests and the study drug concentrations values less than 10 are rounded to one decimal place; the values greater than 10 are rounded to the integer.

Article Snippet: In these cases, HIV infection was confirmed at study sites using a qualitative HIV RNA assay (APTIMA HIV-1 RNA Qualitative Assay, Hologic Gen-Probe INC., San Diego, CA).

Techniques: Infection, Enzyme-linked Immunosorbent Assay, Western Blot, Modification, Next-Generation Sequencing, Mutagenesis